Commercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings ...
With its remote endovascular procedure system currently under review at the FDA, Microbot Medical has put forward positive results from a pivotal study touting a 100% satisfaction rate among ...
BRAINTREE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announces it has received ISO ...
Microbot Medical has secured FDA clearance for the LIBERTY System, the first FDA-approved, single-use, remotely operated robotic system for peripheral endovascular procedures. With the clearance ...
HINGHAM, Mass. - Microbot Medical Inc. (NASDAQ:MBOT) announced today that a study evaluating its LIBERTY Endovascular Robotic System has been published in the Journal of Vascular and Interventional ...
Microbot Medical Inc. (NASDAQ:MBOT) is one of the best-performing NASDAQ stocks according to analysts. On June 17, Microbot Medical announced that it had been granted a patent in China by the China ...
Microbot Medical has received the FDA’s blessing for its miniature, remote-controlled robot for endovascular procedures, designed to offer clinicians the freedom to sit comfortably and operate outside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results